Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Povidone iodine extended release - IVIEW Therapeutics

Drug Profile

Povidone iodine extended release - IVIEW Therapeutics

Alternative Names: In-situ gel povidone iodine ophthalmic drop - IVIEW Therapeutics; IVIEW 1201; IVIEW-1503; Povidone iodine slow releasing eye drop - IVIEW Therapeutics; Sustained release povidone iodine nasal spray - IVIEW Therapeutic; Sustained release povidone iodine ophthalmic drop - IVIEW Therapeutics

Latest Information Update: 06 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IVIEW Therapeutics
  • Class Antiseptics; Antivirals; Disinfectants; Eye disorder therapies; Oxidants; Pyrrolidinones; Skin disorder therapies
  • Mechanism of Action Bacterial protein inhibitors; Bacterial protein modulators; Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Conjunctivitis; COVID 2019 infections

Most Recent Events

  • 28 Sep 2020 Phase-II clinical trials in COVID-2019 infections (Prevention) in Canada (Intranasal) (IVIEW Therapeutics pipeline, September 2020)
  • 28 Sep 2020 Phase-II clinical trials in COVID-2019 infections in Canada (Intranasal) (IVIEW Therapeutics pipeline, September 2020)
  • 16 Sep 2020 IVIEW Therapeutics, St. Paul’s Hospital Sinus Centre and University of British Columbia agree to co-develop povidone iodine formulations for COVID-2019 infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top